Daxor Corp
DXR
Company Profile
Business description
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. The company operates as a single business segment centered on the development, commercialization, and support of its proprietary blood volume analysis technology used by healthcare providers.
Contact
107 Meco Lane
Oak RidgeTN37830
USAT: +1 212 330-8500
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
750
Stocks News & Analysis
stocks
ASX top pick remains cheap despite weaker consumer confidence
Consumer caution dents growth, shares look cheap.
stocks
Chart of the Week: Aussie dividend yields below 10-year average
Income opportunities remain beneath the surface.
stocks
Apple earnings: A smooth transition despite continued memory and supply headwinds
Shares fell as investors digested the latest earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,205.20 | 250.30 | 2.80% |
| CAC 40 | 8,232.33 | 54.44 | 0.67% |
| DAX 40 | 26,475.45 | 37.78 | 0.14% |
| Dow JONES (US) | 53,139.66 | 216.46 | -0.41% |
| FTSE 100 | 10,866.04 | 36.83 | 0.34% |
| HKSE | 24,796.98 | 877.48 | 3.67% |
| NASDAQ | 25,084.61 | 651.91 | -2.53% |
| Nikkei 225 | 61,077.90 | 1,110.73 | -1.79% |
| NZX 50 Index | 14,090.97 | 307.52 | 2.23% |
| S&P 500 | 7,583.61 | 105.01 | -1.37% |
| S&P/ASX 200 | 9,065.10 | 230.60 | 2.61% |
| SSE Composite Index | 3,689.91 | 3.74 | 0.10% |